EUVIMEDEUVIMED entdecken
Crossref

NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction

Xiaocheng Cheng, Hanru Zhao, Xuesong Wen, Guoxing Li, Shuliang Guo, Dongying Zhang

Life Sciences · 2023

DOI: 10.1016/j.lfs.2023.122185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Sciences, 2023. Verfasst von Xiaocheng Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Electro…. Hauptthemen laut MEDLINE: Inflammasomes, Heart Failure. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: The purpose of this study was to evaluate the role of the NLRP3-inflammasome in heart failure with preserved ejection fraction (HFpEF). MAIN METHODS: Serum inflammatory cytokines were detected in patients with heart failure. Correlation analysis was performed to investigate the relationship between serum inflammatory cytokines and left ventricular diastolic function. A 'two-hit' (metabolic stress and mechanical stress) mouse model of HFpEF was established. Furthermore, MCC950 was used to determine the role of NLRP3-inflammasome inhibition in cardiac and pulmonary artery remodelling in HFpEF mice. KEY FINDINGS: Compared with heart failure patients with reduced ejection fraction, patients with HFpEF have significantly elevated serum inflammatory cytokine levels. Serum NLRP3 and interleukin-1β levels were positively correlated with the diastolic function of HFpEF. In the HFpEF mouse model, the inhibition of the NLRP3-inflammasome by MCC950 improved exercise intolerance, glucose intolerance, and left ventricular diastolic function, but had no significant effect on systolic function. Meanwhile, MCC950 attenuated the release of inflammatory cytokines, cardiomyocyte hypertrophy and cardiac fibrosis. Mechanistically, the potential protective effects of MCC950 are achieved by inhibiting activation of the NLRP3-IL-1β pathway and cascade expansion of downstream inflammatory cytokines. Additionally, the inhibition of NLRP3-inflammasome by MCC950 reduced pulmonary artery pressure and improved pulmonary artery remodelling in HFpEF. SIGNIFICANCE: The NLRP3-inflammasome plays a considerable role in inflammation and cardiac and pulmonary artery remodelling in HFpEF by activating the cascade reaction of inflammatory cytokines. This study is the first to comprehensively elucidate the role of the NLRP3-inflammasome in HFpEF, and will provide reference for future study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InflammasomesHeart FailureHumansMiceAnimalsNLR Family, Pyrin Domain-Containing 3 ProteinSulfonesStroke VolumePulmonary ArterySulfonamidesDisease Models, AnimalCytokines

Stichwörter der Autor:innen

Cardiac remodellingHFpEFNLRP3Pulmonary artery

Substanzen

InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinSulfonesSulfonamidesCytokines

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Electronic address: chengxiaocheng@cqmu.edu.cn.
  • Department of Cardiology, Affiliated Banan Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Cardiology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
  • Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

Zitieren

APA

Cheng, X., Zhao, H., Wen, X., Li, G., Guo, S., & Zhang, D. (2023). NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction. Life Sciences. https://doi.org/10.1016/j.lfs.2023.122185

Vancouver

Cheng X, Zhao H, Wen X, Li G, Guo S, Zhang D. NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction. Life Sciences. 2023. doi:10.1016/j.lfs.2023.122185

BibTeX
@article{Cheng2023,
  author = {Cheng, Xiaocheng and Zhao, Hanru and Wen, Xuesong and Li, Guoxing and Guo, Shuliang and Zhang, Dongying},
  title = {NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction},
  journal = {Life Sciences},
  year = {2023},
  doi = {10.1016/j.lfs.2023.122185}
}
Kostenlos starten →